A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521608-23-00

Enrollment

Registered

2026-06-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with unrestectable hepatocellular carcinoma (SLIDE-HCC)

Brief summary

PFS (Progression-Free Survival)

Detailed description

OS (Overall Survival) -ORR (Objective Response Rate) -Safety - Toxicity

Interventions

DRUGTREMELIMUMAB

DRUGDURVALUMAB

DRUGLENVIMA 4 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS (Progression-Free Survival)	—

Secondary

Measure	Time frame
OS (Overall Survival) -ORR (Objective Response Rate) -Safety - Toxicity	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 13, 2026